DelveInsight’s Hypertrophic Cardiomyopathy Market Insights report includes a comprehensive understanding of current treatment practices, hypertrophic cardiomyopathy emerging drugs, market share of individual therapies, and current and forecasted hypertrophic cardiomyopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Hypertrophic Cardiomyopathy Market Report

• As per DelveInsight’s analysis, the hypertrophic cardiomyopathy market is anticipated to grow at a significant CAGR by 2032.
• In the assessment done by DelveInsight, the estimated total diagnosed cases of HCM in the 7MM were 239K in 2022. The highest diagnosed cases of HCM were accounted by the US in 2022 which were approximately 48% of the 7MM. These cases are expected to increase during the forecast period (2023–2032). 
• Leading hypertrophic cardiomyopathy companies such as Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis, and others are developing novel hypertrophic cardiomyopathy drugs that can be available in the hypertrophic cardiomyopathy market in the coming years.
• Some of the key therapies for hypertrophic cardiomyopathy treatment include Aficamten, Mavacamten, IMB-1018972, TN-201, LCZ696, and others. 

 

Discover which therapies are expected to grab the major hypertrophic cardiomyopathy market share @ Hypertrophic Cardiomyopathy Market Report

 

Hypertrophic Cardiomyopathy Overview

Hypertrophic cardiomyopathy is a prevalent inherited cardiac condition that significantly contributes to cardiovascular morbidity and mortality across all age groups. HCM is characterized by unexplained left ventricular hypertrophy and a non-dilated left ventricle, often with preserved or increased ejection fraction. This hypertrophy typically exhibits asymmetry, with the most pronounced thickening in the basal interventricular septum. Over a dozen genes associated with sarcomere proteins have been linked to the development of hypertrophic cardiomyopathy (HCM).

 

Hypertrophic Cardiomyopathy Epidemiology Segmentation

• Hypertrophic Cardiomyopathy Prevalent Cases
• Hypertrophic Cardiomyopathy Diagnosed Cases
• Hypertrophic Cardiomyopathy Gender-specific Diagnosed Cases
• Hypertrophic Cardiomyopathy Type-specific Diagnosed Cases 

 

Download the report to understand which factors are driving hypertrophic cardiomyopathy epidemiology trends @ Hypertrophic Cardiomyopathy Epidemiological Insights

 

Hypertrophic Cardiomyopathy Treatment Market 

CAMZYOS (Mavacamten) is the first FDA-approved cardiac myosin inhibitor designed to address the needs of adults suffering from symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy. Its primary purpose is to enhance functional capacity and alleviate symptoms. CAMZYOS is a selective, allosteric, and reversible inhibitor that specifically targets cardiac myosin. By modulating the number of myosin heads capable of entering the ‘on actin’ state, it reduces the likelihood of force production during systolic and diastolic cross-bridge formation.

 

Learn more about the FDA-approved drugs for hypertrophic cardiomyopathy @ Drugs for Hypertrophic Cardiomyopathy Treatment 

 

Key Hypertrophic Cardiomyopathy Therapies and Companies

• Aficamten: Cytokinetics
• Mavacamten: Bristol-Myers Squibb
• IMB-1018972: Imbria Pharmaceuticals, Inc.
• TN-201: Tenaya Therapeutics
• LCZ696: Novartis

 

To know more about hypertrophic cardiomyopathy clinical trials, visit @ Hypertrophic Cardiomyopathy Treatment Drugs 

 

Hypertrophic Cardiomyopathy Market Dynamics

The hypertrophic cardiomyopathy market dynamics are anticipated to change in the coming years. In the realm of hypertrophic cardiomyopathy treatment, various approaches exist alongside pharmacotherapy, including septal myectomy and septal alcohol ablation, which are considered comparable procedures for addressing hypertrophic obstructive cardiomyopathy (HOCM). The pivotal tool for diagnosing HCM remains echocardiography, and the potential role of MRI in assessing the risk of sudden cardiac death is on the horizon. It is crucial to differentiate between genetically mediated phenocopies and physiologic remodeling resulting from fitness, as these distinctions can significantly impact management strategies. As our understanding of the genetic basis of HCM continues to expand, genetic testing holds promise for providing deeper insights. 

 

Scope of the Hypertrophic Cardiomyopathy Market Report

• Therapeutic Assessment: Hypertrophic Cardiomyopathy current marketed and emerging therapies
• Hypertrophic Cardiomyopathy Market Dynamics: Attribute Analysis of Emerging Hypertrophic Cardiomyopathy Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Hypertrophic Cardiomyopathy Market Access and Reimbursement

 

Discover more about hypertrophic cardiomyopathy drugs in development @ Hypertrophic Cardiomyopathy Clinical Trials

 

Table of Contents

1. Key Insights

2. Executive Summary of Hypertrophic Cardiomyopathy (HCM)

3. Competitive Intelligence Analysis for Hypertrophic Cardiomyopathy (HCM)

4. Hypertrophic Cardiomyopathy (HCM): Market Overview at a Glance

5. Hypertrophic Cardiomyopathy (HCM): Disease Background and Overview

6. Patient Journey

7. Hypertrophic Cardiomyopathy (HCM) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Hypertrophic Cardiomyopathy (HCM) Unmet Needs

10. Key Endpoints of Hypertrophic Cardiomyopathy (HCM) Treatment

11. Hypertrophic Cardiomyopathy (HCM) Marketed Products

12. Hypertrophic Cardiomyopathy (HCM) Emerging Therapies

13. Hypertrophic Cardiomyopathy (HCM): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hypertrophic Cardiomyopathy (HCM)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services